Isolation and characterization of novel inhibitors of sphingolipid synthesis: australifungin, viridiofungins, rustmicin, and khafrefungin.
Mandala
S M
SM
Department of Infectious Disease, Merck Research Laboratories, Rahway, New Jersey 07065-4607, USA.
Harris
G H
GH
D000217:Acyltransferases / Q000037:antagonists & inhibitors; D000598:Amino Acids, Cyclic / Q000302:isolation & purification*; D001681:Biological Assay; D002951:Citrates / Q000302:isolation & purification*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000302:isolation & purification; D006017:Glycolipids / Q000302:isolation & purification*; D007783:Lactones / Q000302:isolation & purification; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D051102:Serine C-Palmitoyltransferase; D013107:Sphingolipids / Q000096:biosynthesis*; D013764:Tetrahydronaphthalenes / Q000302:isolation & purification*
D000598:Amino Acids, Cyclic; D002951:Citrates; D004791:Enzyme Inhibitors; D006017:Glycolipids; D007783:Lactones; D013107:Sphingolipids; D013764:Tetrahydronaphthalenes; C094344:australifungin; C109747:khafrefungin; C047784:rustmicin; D010088:Oxidoreductases; C108138:dihydroceramide desaturase; D000217:Acyltransferases; D051102:Serine C-Palmitoyltransferase